Which peptides are studied in relation to peripheral nerve regeneration?
A research-supply review of the peptides and growth-factor proteins studied in peripheral nerve regeneration models, including FGF-2 delivered from engineered nerve wraps and bone-derived conduit studies in rats.
The peptide most directly studied in relation to peripheral nerve regeneration in the supplied evidence is fibroblast growth factor-2 (FGF-2), also called basic fibroblast growth factor (bFGF), a heparin-binding growth factor protein of the FGF family. In the work cited here it is used as an engineered thermostable variant, not as the native sequence, and it is delivered from a composite biomaterial rather than administered on its own [1]. The evidence block does not give a sequence, molecular formula, or molecular weight for FGF-2, so none is stated here. The second body of work in this evidence set does not centre on a peptide at all: it compares decalcified and decellularized bone conduits fabricated from rat femoral diaphysis and chicken ulna, implanted to bridge 10 mm sciatic nerve gaps in rats, with functional recovery assessed over 16 weeks [2].
The mechanistic work in the FGF-2 study centres on growth factor signalling released from a hydrogel interface, where the inorganic phase of the composite governs how much factor is released and over what period [1].
Research Studies
FGF-2 and controlled release from a GelMA/Laponite nerve wrap
A biofunctional nanocomposite nerve interface was developed by combining an ion-covalent gelatin methacryloyl (GelMA)/Laponite hydrogel with engineered thermostable FGF-2, with the stated aim of recreating a regenerative microenvironment at the site of peripheral nerve transection [1]. Laponite incorporation at 2%–2.5% w/v modulated the hydrogel network, and the reported consequences were shear-thinning behaviour, enhanced viscoelasticity, microporosity, a twofold increase in compressive modulus, controlled degradation, injectability, and three-dimensional bioprintability [1]. Functionalization with the thermostable FGF-2 enabled sustained release [1]. The study is a materials-and-delivery study; the release behaviour and the functional regeneration endpoints described belong to that experimental system, not to FGF-2 as a standalone research material.
FGF-2 and the Laponite network as the release-controlling variable
The distinguishing feature of this work is that the inorganic component, not the protein alone, is treated as the variable that sets release. Laponite concentration between 2% and 2.5% w/v is reported to have precisely modulated the hydrogel network, and the same range is associated with the mechanical and printing properties listed above [1]. Because the release profile is attributed to the network rather than to the factor in isolation, any reading of this study as evidence about FGF-2 dosing or exposure is outside what the data support.
FGF-2 in a 3D-printed nerve wrap interface
The construct is described as a 3D-printed nerve wrap interface, meaning the delivery format is a printed, conformable material placed at the injury site rather than an injected solution [1]. The stated context is peripheral nerve transection, a injury class for which surgical treatment is used and for which functional recovery is described as remaining incomplete [1]. The engineered thermostable FGF-2 is the peptide component of that interface.
Bone-derived conduits and the 10 mm rat sciatic gap model
In the comparative conduit study, peripheral nerve injuries are framed as a clinical challenge particularly when nerve gaps exceed 5 mm and spontaneous regeneration is inadequate [2]. Demineralized and decellularized bone scaffolds were characterized for collagen preservation, luminal geometry, and mechanical and electrical properties, then implanted to bridge 10 mm sciatic nerve gaps in rats, with functional recovery assessed over 16 weeks [2]. This is an in vivo rodent study; the conduits are bone-derived rather than peptide-based, and the findings are specific to the rat sciatic model and the two conduit sources tested.
Rat femur versus chicken ulna conduit material
The two conduit sources compared were rat femoral diaphysis and chicken ulna, evaluated as alternatives to conventional autologous and allogeneic grafts [2]. The comparison is between materials and species of origin, not between peptides. The table below sets out what the evidence block states about each line of work.
| Study | Active component | Model or format | Reported focus |
|---|---|---|---|
| GelMA/Laponite nerve wrap [1] | Engineered thermostable FGF-2 | 3D-printed nanocomposite nerve interface; peripheral nerve transection | Laponite at 2%–2.5% w/v modulated the network; sustained FGF-2 release; twofold increase in compressive modulus |
| Bone conduit comparison [2] | Demineralized, decellularized bone | 10 mm sciatic nerve gap in rats; 16-week functional assessment | Collagen preservation, luminal geometry, mechanical and electrical properties; comparison of rat femur and chicken ulna conduits |
Where the evidence is animal-only or in vitro
Both lines of work described above are preclinical. The conduit comparison is explicitly an in vivo study in rats, with a 10 mm sciatic gap and a 16-week recovery window [2]. The FGF-2 nerve wrap work is a materials development and delivery study reporting hydrogel characterization and functional regeneration outcomes in its experimental system [1]. No human trial data appear in this evidence block for either line of work, and no human dose, exposure, or outcome is reported.
Adjacent neuromodulatory work that is not peptide-focused
A separate hypothesis paper discusses peripheral nerve injury and incomplete functional recovery, and proposes a triple neuromodulatory axis involving Hericium erinaceus, lithium, and vitamin B12, each of which is described as having individually demonstrated promising neuromodulatory activity [3]. This is a hypothesis paper rather than a peptide study, and it is included here only to mark the boundary of the topic: the compounds it discusses are a fungal extract, a mineral, and a vitamin, not peptides.
What the evidence does not establish
The evidence block does not provide sequence, formula, or molecular weight data for FGF-2, does not report a dose for any compound, and does not report human outcomes for any intervention described. Claims about comparative efficacy between the FGF-2 nerve wrap and the bone conduits cannot be made from these sources, because the two studies use different models, materials, and endpoints [1][2].
If you are reading this for personal health reasons
The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Laponite Network Controls FGF-2 Release and Drives Functional Nerve Regeneration via 3D-Printed Nerve Wrap Interfaces — https://pubmed.ncbi.nlm.nih.gov/42695428/
- [2] Decalcified and Decellularized Bone Conduits for Peripheral Nerve Regeneration: A Comparative In Vivo Study Using Rat Femur and Chicken Ulna Conduits — https://europepmc.org/article/PMC/PMC13544568
- [3] Peripheral nerve regeneration and synergistic pharmacology using Hericium erinaceus, lithium, and vitamin B12: The triple neuromodulatory axis hypothesis — https://pubmed.ncbi.nlm.nih.gov/41878942/